摘要
肠道菌群是指定植在人体肠道内并与人体相互影响的微生物群,在人体中发挥重要作用,可以通过调节宿主的基础代谢与免疫,维持人体内环境的稳态。一旦肠道菌群失调,可以导致多系统疾病。桥本甲状腺炎是一种器官特异性自身免疫性疾病,该病的发病机制复杂,且发病率逐年升高,正逐渐成为影响全球的严重公共卫生疾病。近年来,肠道菌群和桥本甲状腺炎的关系受到广泛关注。已有大量研究证实,与健康人群相比,桥本甲状腺炎患者肠道菌群的丰富度与多样性有所改变。研究表明,传统的中医疗法能通过调控肠道菌群发挥治疗该病的作用。该文从二者的关系以及中医药通过调控肠道菌群治疗桥本甲状腺炎出发,系统总结了相关研究,为该领域的研究提供一定的参考。
Gut microbiota is the microbial community that is specifically planted in the human gut and interacts with the human body.It plays an important role in the human body by regulating the basal metabolism and immunity of the host to maintain the homeostasis of the human body.Once the intestinal flora is dysregulated,it can lead to multi-system diseases.Hashimoto′s thyroiditis is an organ-specific autoimmune disease.The pathogenesis of Hashimoto′s thyroiditis is complex and its incidence is increasing year by year,which is gradually becoming a serious public health disease affecting the world.In recent years,the relationship between gut microbiota and bridge onychitis has received extensive attention.A large number of studies have shown that the richness and diversity of intestinal flora in Hashimoto′s thyroiditis patients are changed compared with healthy people.Studies have shown that traditional Chinese medicine therapy can play a role in treating this disease by regulating intestinal flora.This article systematically summarizes the relationship between the two and the effect of traditional Chinese medicine on the treatment of bridge onychitis by regulating intestinal flora,so as to provide some reference for research in this field.
作者
万斌
陈正涛
冷玉琳
韩雨桐
谢红艳
高泓
谢春光
WAN Bin;CHEN Zhengtao;LENG Yulin;HAN Yutong;XIE Hongyan;GAO Hong;XIE Chunguang(Hospital of Chengdu University of Traditional Chinese Medicine(TCM),Chengdu 610072,China;Affiliated Hospital of Jiangxi University of Chinese Medicine,Nanchang 330006,China;TCM Regulation Metabolic Diseases Key Laboratory of Sichuan Province,Chengdu 610072,China)
出处
《世界科学技术-中医药现代化》
北大核心
2025年第3期626-632,共7页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家中医药管理局人才支持项目(国中医药人教函[2022]6号):岐黄学者,负责人:谢春光
国家中医药管理局中医药传承创新团队及人才支持项目(ZYYCXTD-C-202209):中医药防治糖尿病大血管病变传承创新团队,负责人:谢春光
四川省中医药科技产业创新团队项目(2022C012):中医药防治内分泌代谢性疾病科技产业创新团队,负责人:谢春光。
关键词
肠道菌群
桥本甲状腺炎
中医药
粪菌移植
Intestinal flora
Hashimoto thyroiditis
TCM therapy
Fecal microbiota transplantation
